Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.
Saved in:
| Title: | Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. |
|---|---|
| Authors: | Tan CR; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gordan L; Florida Cancer Specialists & Research Institute, Tampa, FL, USA., Richter J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., DiLeo R; Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA., Mewawalla P; Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA., Larson S; Department of Medicine, Hematology/Oncology, UCLA Health, Los Angeles, CA, USA., Davies F; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Oveisi D; Department of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Gupta-Werner N; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Medhekar R; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Yin X; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Cortoos A; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Armoon M; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Thompson-Leduc P; Analysis Group ULC, Montreal, QC, Canada., Rahman A; Analysis Group ULC, Montreal, QC, Canada., Tardif-Samson A; Analysis Group ULC, Montreal, QC, Canada., Vanden Eynde C; Analysis Group ULC, Montreal, QC, Canada., Reitan J; RJM Group LLC, Crown Point, IN, USA., Milkovich G; RJM Group LLC, Crown Point, IN, USA., Bubalo J; Pharmacy Services, Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA., Forman A; Ascension Providence Hospital, Southfield, MI, USA., Bryan B; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Sborov D; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Kaila S; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Usmani S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2026 Jul 14, pp. 1-9. Date of Electronic Publication: 2026 Jul 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42444515 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tan+CR%22">Tan CR</searchLink>; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Gordan+L%22">Gordan L</searchLink>; Florida Cancer Specialists & Research Institute, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Richter+J%22">Richter J</searchLink>; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22DiLeo+R%22">DiLeo R</searchLink>; Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Mewawalla+P%22">Mewawalla P</searchLink>; Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Larson+S%22">Larson S</searchLink>; Department of Medicine, Hematology/Oncology, UCLA Health, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Davies+F%22">Davies F</searchLink>; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Oveisi+D%22">Oveisi D</searchLink>; Department of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Gupta-Werner+N%22">Gupta-Werner N</searchLink>; Johnson & Johnson Innovative Medicine, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Medhekar+R%22">Medhekar R</searchLink>; Johnson & Johnson Innovative Medicine, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Yin+X%22">Yin X</searchLink>; Johnson & Johnson Innovative Medicine, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Cortoos+A%22">Cortoos A</searchLink>; Johnson & Johnson Innovative Medicine, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Armoon+M%22">Armoon M</searchLink>; Johnson & Johnson Innovative Medicine, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Thompson-Leduc+P%22">Thompson-Leduc P</searchLink>; Analysis Group ULC, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Rahman+A%22">Rahman A</searchLink>; Analysis Group ULC, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Tardif-Samson+A%22">Tardif-Samson A</searchLink>; Analysis Group ULC, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Vanden+Eynde+C%22">Vanden Eynde C</searchLink>; Analysis Group ULC, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Reitan+J%22">Reitan J</searchLink>; RJM Group LLC, Crown Point, IN, USA.<br /><searchLink fieldCode="AU" term="%22Milkovich+G%22">Milkovich G</searchLink>; RJM Group LLC, Crown Point, IN, USA.<br /><searchLink fieldCode="AU" term="%22Bubalo+J%22">Bubalo J</searchLink>; Pharmacy Services, Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Forman+A%22">Forman A</searchLink>; Ascension Providence Hospital, Southfield, MI, USA.<br /><searchLink fieldCode="AU" term="%22Bryan+B%22">Bryan B</searchLink>; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Sborov+D%22">Sborov D</searchLink>; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Kaila+S%22">Kaila S</searchLink>; Johnson & Johnson Innovative Medicine, Horsham, PA, USA.<br /><searchLink fieldCode="AU" term="%22Usmani+S%22">Usmani S</searchLink>; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2026 Jul 14, pp. 1-9. <i>Date of Electronic Publication: </i>2026 Jul 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42444515 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/14796694.2026.2698699 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1 Titles: – TitleFull: Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tan CR – PersonEntity: Name: NameFull: Gordan L – PersonEntity: Name: NameFull: Richter J – PersonEntity: Name: NameFull: DiLeo R – PersonEntity: Name: NameFull: Mewawalla P – PersonEntity: Name: NameFull: Larson S – PersonEntity: Name: NameFull: Davies F – PersonEntity: Name: NameFull: Oveisi D – PersonEntity: Name: NameFull: Gupta-Werner N – PersonEntity: Name: NameFull: Medhekar R – PersonEntity: Name: NameFull: Yin X – PersonEntity: Name: NameFull: Cortoos A – PersonEntity: Name: NameFull: Armoon M – PersonEntity: Name: NameFull: Thompson-Leduc P – PersonEntity: Name: NameFull: Rahman A – PersonEntity: Name: NameFull: Tardif-Samson A – PersonEntity: Name: NameFull: Vanden Eynde C – PersonEntity: Name: NameFull: Reitan J – PersonEntity: Name: NameFull: Milkovich G – PersonEntity: Name: NameFull: Bubalo J – PersonEntity: Name: NameFull: Forman A – PersonEntity: Name: NameFull: Bryan B – PersonEntity: Name: NameFull: Sborov D – PersonEntity: Name: NameFull: Kaila S – PersonEntity: Name: NameFull: Usmani S IsPartOfRelationships: – BibEntity: Dates: – D: 14 M: 07 Text: 2026 Jul 14 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1744-8301 Titles: – TitleFull: Future oncology (London, England) Type: main |
| ResultId | 1 |
